Repeat Percutaneous Radiofrequency Ablation of T1 Renal Cell Carcinomas is Safe in Patients with Von Hippel-Lindau Disease.
Radiofrequency ablation
Renal cell carcinoma
Renal mass
Renal tumor
Von Hippel–Lindau disease
Journal
Cardiovascular and interventional radiology
ISSN: 1432-086X
Titre abrégé: Cardiovasc Intervent Radiol
Pays: United States
ID NLM: 8003538
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
18
04
2021
accepted:
22
07
2021
pubmed:
21
8
2021
medline:
1
12
2021
entrez:
20
8
2021
Statut:
ppublish
Résumé
Patients with Von Hippel-Lindau disease often develop multifocal, metachronous renal cell carcinomas which require therapy. The purpose of this retrospective single-center study is to evaluate the outcomes of radiofrequency ablation (RFA) in the treatment of renal cell carcinomas in patients with Von Hippel-Lindau disease. 9 patients (4 male, 5 female, 47.9 ± 10.7 y/o) with Von Hippel-Lindau disease underwent 18 CT-guided percutaneous RFA procedures for the treatment 21 renal cell carcinomas (largest diameter: 32.9 ± 8.6 mm, cT1a: 16, cT1b: 5). Seven patients were previously treated either by partial or radical nephrectomy. Technical success, effectiveness, safety, progression-free survival, overall survival and tumor characteristics were analyzed. All RFA procedures were technically successful without major complications. There were 5 minor complications. No residual or recurrent tumor was seen in the ablation zone during a follow-up of 34.0 ± 18.1 months (0-58 months). No patient required dialysis during follow-up. One patient died after 63 months after the first treatment due to complications from a cerebellar hemangioblastoma. No endpoint was reached for overall or progression-free survival. The results from this limited case series suggest that RFA of RCCs in patients with VHL is a safe and effective therapy, which can preserve sufficient renal function even after renal surgery.
Identifiants
pubmed: 34414496
doi: 10.1007/s00270-021-02935-w
pii: 10.1007/s00270-021-02935-w
pmc: PMC8626382
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2022-2025Informations de copyright
© 2021. The Author(s).
Références
Acta Radiol. 2011 Jul 1;52(6):680-5
pubmed: 21525107
Int J Hyperthermia. 2012;28(3):227-34
pubmed: 22515344
Fam Cancer. 2011 Sep;10(3):529-34
pubmed: 21503747
J Urol. 2008 Jan;179(1):67-70
pubmed: 17997447
J Vasc Interv Radiol. 2003 Sep;14(9 Pt 2):S199-202
pubmed: 14514818
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
J Urol. 2017 Sep;198(3):520-529
pubmed: 28479239
Urol Oncol. 2013 Jul;31(5):686-92
pubmed: 21723752
Hum Pathol. 1988 Sep;19(9):1072-9
pubmed: 3417291
Cardiovasc Intervent Radiol. 2017 Aug;40(8):1141-1146
pubmed: 28584945
Q J Med. 1990 Nov;77(283):1151-63
pubmed: 2274658
J Urol. 2004 Jul;172(1):63-5
pubmed: 15201738
Acta Radiol. 2005 Apr;46(2):208-14
pubmed: 15902899
J Urol. 2010 May;183(5):1703-7
pubmed: 20299060
Transl Androl Urol. 2019 Dec;8(6):601-608
pubmed: 32038956
Radiology. 2014 Oct;273(1):241-60
pubmed: 24927329
Cent European J Urol. 2020;73(2):167-172
pubmed: 32782836
J Urol. 1995 Dec;154(6):2010-4; discussion 2014-5
pubmed: 7500446
Urology. 2007 Sep;70(3):435-9
pubmed: 17905091